Positive results from Lilly’s interim antibody trial data
Analysts expect antibody treatments could help some patients, as broad distribution of Covid-19 vaccine candidates is expected to be lengthy
16 September 2020 - 16:31
Los Angeles — Eli Lilly said on Wednesday that interim trial data showed its experimental antibody treatment reduced the need for hospitalisation and emergency room visits for patients with moderate Covid-19.
Lilly’s mid-stage study tested three different doses of LY-CoV555, an antibody treatment designed to recognise and lock onto the novel coronavirus, thus preventing the infection from spreading...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.